UBS Group
LAB icon

UBS Group’s Standard BioTools LAB Stock Holding History

UBS Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-100
Closed -$3K – 9080
2014
Q4 		$3K Buy
+100
New +$2.83K ﹤0.01% 9241

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

UBS Group's LAB Position: Q2 2026 in Review

UBS Group increased its Standard BioTools (LAB) stake by 40% in Q2 2026, buying an estimated $114K and bringing the position to 425,977 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #6450.

UBS Group first reported a position in LAB in Q4 2014 and has held it in 47 quarters since. The position peaked at $5.19M in Q3 2021. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • UBS Group held 425,977 shares of Standard BioTools worth $351K as of Q2 2026.
  • UBS Group bought 120,855 Standard BioTools shares in Q2 2026, an estimated $114K.
  • Standard BioTools made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6450 holding.
  • UBS Group first reported a position in Standard BioTools in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Standard BioTools position peaked at $5.19M in Q3 2021.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.